retatrutide parkinson's disease trial clinical GLP-1 Agonists: A New Frontier in Parkinson's Treatment? Update on Retatrutide - by
Description
P.GholamiS.et al (2019)
To visualise the vessels, Alexa Fluor 488-conjugated WGA (Thermo Fisher Scientific, W11261
Gastrointestinal symptoms typically improve over time as the body adapts to the medication, though the timeframe varies between individuals
Gallbladder and biliary system assessment , given the potential risk for gallbladder disease associated with incretin therapies
